# Citius Pharmaceuticals, Inc.: overview CTXR · Nasdaq · CIK 1506251 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/ctxr.md) · [Financials](/companies/ctxr/financials.md) · [Filings](/companies/ctxr/filings.md) · [Insiders](/companies/ctxr/insiders.md) Latest reported revenue: [$1.5m](/filings/0001213900-26-090185.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-090185). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | [3,944](/filings/0001213900-26-015878.md) | [1,667](/filings/0001213900-26-057842.md) | [1,494](/filings/0001213900-26-090185.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | [80.0%](/filings/0001213900-26-015878.md) | [80.3%](/filings/0001213900-26-057842.md) | [67.1%](/filings/0001213900-26-090185.md) | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | [(228.7%)](/filings/0001213900-26-015878.md) | [(1931.0%)](/filings/0001213900-26-057842.md) | [(785.4%)](/filings/0001213900-26-090185.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | [(238.2%)](/filings/0001213900-26-090185.md) | [(1685.9%)](/filings/0001213900-26-090185.md) | [(797.9%)](/filings/0001213900-26-090185.md) | | Diluted EPS | $ per share | not reported | [(1.30)](/filings/0001213900-26-015878.md) | [(1.27)](/filings/0001213900-26-057842.md) | [(0.80)](/filings/0001213900-26-090185.md) | not reported | [(0.38)](/filings/0001213900-26-015878.md) | [(0.95)](/filings/0001213900-26-057842.md) | [(0.34)](/filings/0001213900-26-090185.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001213900-22-082217.md) | [0.1](/filings/0001213900-22-082217.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(26146.5%)](/filings/0001213900-22-082217.md) | [(37017.8%)](/filings/0001213900-23-099889.md) | not reported | not reported | not reported | | Net margin | % | [(25616.0%)](/filings/0001213900-22-082217.md) | [(37378.5%)](/filings/0001213900-23-099889.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.23)](/filings/0001213900-22-082217.md) | [(0.23)](/filings/0001213900-22-082217.md) | [(5.57)](/filings/0001213900-24-113149.md) | [(5.97)](/filings/0001213900-25-125333.md) | [(3.38)](/filings/0001213900-25-125333.md) | | Free cash flow | $m | [(24.3)](/filings/0001213900-22-082217.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Net income: us-gaap:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ctxr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $130.3k | 215,537 | | Reduced −30,621 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $119.4k | 197,364 | | Added +29,626 | | [Miller Financial Services LLC](/funds/2022893.md) | 2026-06-30 | $78.6k | 130,000 | | Added +116,000 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $75.5k | 124,910 | | New +124,910 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $74.3k | 122,837 | | Added +100,314 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $47.0k | 77,755 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $42.2k | 69,850 | | Reduced −1 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $37.9k | 62,742 | | Added +18,768 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $35.8k | 59,199 | | Added +37,904 | | [Asset Advisory Group, Inc.](/funds/2110402.md) | 2026-06-30 | $35.7k | 59,011 | | Unchanged | ## Recent filings [All 630 filings](/companies/ctxr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 16:05 ET | [8-K](/filings/0001213900-26-112478.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-112478 | | 2026-08-21 | 16:15 ET | [8-K](/filings/0001213900-26-092604.md) | 3.01 Delisting notice | 0001213900-26-092604 | | 2026-08-14 | 16:35 ET | [10-Q](/filings/0001213900-26-090185.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090185 | | 2026-08-14 | 16:35 ET | [8-K](/filings/0001213900-26-090181.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-090181 | | 2026-08-05 | 09:27 ET | [8-K](/filings/0001213900-26-085432.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-085432 | | 2026-06-01 | 16:30 ET | [8-K](/filings/0001213900-26-063531.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-063531 | | 2026-05-15 | 16:41 ET | [8-K](/filings/0001213900-26-057876.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-057876 | | 2026-05-15 | 16:31 ET | [10-Q](/filings/0001213900-26-057842.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057842 | | 2026-05-08 | 16:30 ET | [8-K](/filings/0001213900-26-053916.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-053916 | | 2026-04-29 | 16:30 ET | [8-K](/filings/0001213900-26-049338.md) | 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-049338 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001213900-25-125333.md), filed Dec 23, 2025. ## Forecast league Q4 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/d2bdf71b-1859-42c0-81eb-1ee6c27c73fc) ## About the filer - CIK: 1506251 - Tickers: CTXR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:06 ET. No prices; not investment advice.